bioMérieux Clinical | Press releases

Data from Clinical Studies of bioTheranostics’ CancerTYPE ID^® and Breast Cancer Index^® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting*

Sun, 6 Jun 2010 00:00:00 +0200

bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID^® and Breast Cancer Index^® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

bioMérieux Showcases Myla™ at ASM 2010: New Informatics Solution to Transform the Microbiology Laboratory

Tue, 25 May 2010 00:00:00 +0200

Innovative solution optimizes laboratory workflow and clinical information management. A world leader in in vitro diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux’s FMLA™* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple dashboard-based user interface that provides full control of lab workflow.

Shimadzu and bioMérieux Enter into Partnership for Mass Spectrometry Applications in Microbiology

Fri, 21 May 2010 00:00:00 +0200

Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec.

bioMérieux and GlaxoSmithKline Enter into Alliance to Develop Molecular Theranostic Test for Cancer Treatment Selection

Mon, 10 May 2010 00:00:00 +0200

bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer).

bioMérieux and Knome Sign Strategic Partnership

Wed, 21 Apr 2010 00:00:00 +0200

Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome.

bioMérieux Introduces Myla™ at ECCMID: New Informatics Solution to Transform the Microbiology Laboratory

Mon, 12 Apr 2010 00:00:00 +0200

Innovative software:

consolidates and transforms microbiology laboratory data into actionable information for treatment decisions
recaptures time for lab managers through efficiency gains and full control of lab workflow

A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. For more information, visit www.mylahelps.com.

bioMérieux Acquires from AnagnosTec - Database and Expertise for Rapid Microbial Identification Using Mass Spectrometry

Mon, 12 Apr 2010 00:00:00 +0200

bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology.

bioMérieux’s PREVI™ Isola Wins the 2010 - Medical Design Excellence Award

Thu, 8 Apr 2010 00:00:00 +0200

The award highlights the automated media streaker’s breakthrough technology.
A world leader in in vitro diagnostics, bioMérieux announced today that its automated media streaker, PREVI™ Isola has received a 2010 Medical Design Excellence Award for contributions and advances in the design of medical products. This exclusive award recognizes products for their design and engineering features, including user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. PREVI Isola was designed to revolutionize front-end media processing tasks, and it is a critical component in bioMérieux’s complete range of solutions and services for Full Microbiology Lab Automation (FMLA™): www.biomerieux-diagnostics.com/fmla

Philips and bioMérieux announce partnership to develop and market next-generation handheld diagnostic solutions for Point-of-Care

Thu, 7 Jan 2010 00:00:00 +0100

Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.
Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)).

bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment

Tue, 17 Nov 2009 00:00:00 +0100

bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.

New A(H1N1) Strain Added to bioMérieux’s Molecular Diagnostic Test NucliSENS EasyQ® Influenza A/B

Thu, 12 Nov 2009 00:00:00 +0100

A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain.

bioMérieux Launches a Molecular Diagnostic MRSA Test on its EasyQ® Automated Platform

Fri, 6 Nov 2009 00:00:00 +0100

Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010.

2nd World HAI Forum: Experts Discuss Looming Threats to Patient Safety

Wed, 23 Sep 2009 00:00:00 +0200

Newly evolved enzymes make some bacteria resistant to all common antibiotics
Healthcare workers slow to receive flu vaccines
Countries not doing enough to combat “superbugs”

About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each year
According to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of defense. Second threat: healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming to work when they are ill rather than taking sick days. Third threat: Health ministries are failing to adopt proven health policies that could limit the spread of infections in hospitals and other healthcare establishments.

bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious Mononucleosis

Tue, 30 Jun 2009 00:00:00 +0200

bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva.

bioMérieux Launches Molecular Biology Test, NucliSENS EasyQ® HIV-1 v2.0, for Improved Care of Patients with HIV

New test can be used with the first CE marked Dry Blood Spot sample collection technique for viral load monitoring, bringing testing to patients in remote locations

Tue, 19 May 2009 00:00:00 +0200

bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today.

bioMérieux: Enhancing the Productivity of Microbiology Laboratories with the LeanSigma® Method

Fri, 15 May 2009 00:00:00 +0200

bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology.

2009 ESCMID/bioMérieux Research Grant in Clinical Microbiology

Winner Conducting Research on Major Cause of Healthcare-Associated Infections

Tue, 12 May 2009 00:00:00 +0200

bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe.

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

Sun, 14 Dec 2008 00:00:00 +0100

Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients.

bioMérieux to Develop New Highly-Specific, Non-invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies

Thu, 25 Sep 2008 00:00:00 +0200

Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone.

bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx

Thu, 11 Sep 2008 00:00:00 +0200

bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.